Gilead Sciences, Inc. is calling off its effort to pursue accelerated approval of magrolimab in myelodysplastic syndrome (MDS), while the US Food and Drug Administration has placed partial clinical holds on additional Phase II trials of the drug, in multiple myeloma and diffuse large B-cell lymphoma (DLBCL), the company said in its fourth quarter earnings report.
Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds
Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty
The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.
More from Earnings
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.